HELIOS-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

drug protocol number
ALN-TTRSC02-003
drug sponsor
Alnylam Pharmaceuticals.
drug study
ALN-TTRSC02 (Vutrisiran)
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase